Neglected diseases

Leishmaniasis Clinical Trial Pipeline Highlights 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 10, 2019
Health, Clinical trials, Infectious diseases, Pharmaceutical, Infectious diseases, Health, Medical specialties, Neglected diseases, RTT, Clinical research, Design of experiments, Drug discovery, Leishmaniasis, Clinical trial, Visceral leishmaniasis, Center for Infectious Disease Research

The "Global Leishmaniasis Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Leishmaniasis Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.
  • Leishmaniasis Pipeline Highlights - 2019, provides most up-to-date information on key pipeline products in the global Leishmaniasis market.
  • It covers emerging therapies for Leishmaniasis in active clinical development stages including early and late stage clinical trials.
  • The report provides Leishmaniasis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Experts Discuss Decentralized Manufacturing to Tackle Neglected Tropical Diseases and Promote Universal Health Coverage at World Health Assembly Event

Retrieved on: 
Wednesday, May 22, 2019
Articles, Health, Medical specialties, Tropical diseases, Sanitation, Neglected tropical diseases, NTDS, Neglected diseases, Biopharmaceutical, Global Network for Neglected Tropical Diseases, Neglected tropical disease research and development

How can decentralized manufacturing be part of an integrated approach to tackling NTDs and advancing Universal Health Coverage?

Key Points: 
  • How can decentralized manufacturing be part of an integrated approach to tackling NTDs and advancing Universal Health Coverage?
  • "We, like the World Health Organization, aim to tackle these global challenges and offer a better quality of life."
  • The panel discussed the role of decentralized manufacturing as a strategy to address the problem of accessing medicines and biologics and tackling NTDs.
  • Neglected tropical diseases (NTDs) are a set of 17 diseases that disproportionately affect more than 1 billion people living primarily in the developing world.

Experts Discuss Decentralized Manufacturing to Tackle Neglected Tropical Diseases and Promote Universal Health Coverage at World Health Assembly Event

Retrieved on: 
Wednesday, May 22, 2019
Articles, Health, Medical specialties, Tropical diseases, Sanitation, Neglected tropical diseases, NTDS, Neglected diseases, Biopharmaceutical, Global Network for Neglected Tropical Diseases, Neglected tropical disease research and development

How can decentralized manufacturing be part of an integrated approach to tackling NTDs and advancing Universal Health Coverage?

Key Points: 
  • How can decentralized manufacturing be part of an integrated approach to tackling NTDs and advancing Universal Health Coverage?
  • "We, like the World Health Organization, aim to tackle these global challenges and offer a better quality of life."
  • The panel discussed the role of decentralized manufacturing as a strategy to address the problem of accessing medicines and biologics and tackling NTDs.
  • Neglected tropical diseases (NTDs) are a set of 17 diseases that disproportionately affect more than 1 billion people living primarily in the developing world.

First FDA-approved vaccine for the prevention of dengue disease in endemic regions

Retrieved on: 
Thursday, May 2, 2019
Infectious diseases, Dengue fever, Medical specialties, Medicine, Neglected diseases, Tropical diseases, Flaviviruses, Dengue virus, Viral hemorrhagic fever, Dengue fever outbreaks, Mosquito-borne disease

While there is no cure for dengue disease, today's approval is an important step toward helping to reduce the impact of this virus in endemic regions of the United States."

Key Points: 
  • While there is no cure for dengue disease, today's approval is an important step toward helping to reduce the impact of this virus in endemic regions of the United States."
  • A subsequent infection can lead to severe dengue, including dengue hemorrhagic fever (DHF), a more severe form of the disease that can be fatal.
  • "As the second infection with dengue is often much more severe than the first, the FDA's approval of this vaccine will help protect people previously infected with dengue virus from subsequent development of dengue disease."
  • The vaccine was determined to be approximately 76 percent effective in preventing symptomatic, laboratory-confirmed dengue disease in individuals 9 through 16 years of age who previously had laboratory-confirmed dengue disease.

DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases

Retrieved on: 
Tuesday, April 16, 2019
Technology, Other Technology, Health, Biotechnology, Infectious diseases, Pharmaceutical, Research, Science, Infectious diseases, Medical specialties, Medicine, Tropical diseases, Neglected diseases, Drug discovery, Drugs for Neglected Diseases Initiative, Neglected tropical diseases, Chagas disease, Chagas: Time to Treat campaign, Neglected tropical disease research and development

Atomwise, Inc., a biotech company using artificial intelligence (AI) for drug discovery, and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development organization working to deliver new treatments for neglected diseases, today announced that promising drug-like compounds have been discovered in a program to develop first-in-class treatments for Chagas disease.

Key Points: 
  • Atomwise, Inc., a biotech company using artificial intelligence (AI) for drug discovery, and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development organization working to deliver new treatments for neglected diseases, today announced that promising drug-like compounds have been discovered in a program to develop first-in-class treatments for Chagas disease.
  • For each disease protein, Atomwise screened millions of compounds using its AI-powered screening technology to predict those that bind and potentially inhibit protein function.
  • This research has delivered drug-like compounds that will now go on to further optimization and then potential drug development.
  • Atomwise has raised over $50 million from leading venture capital firms to support the development and application of its AI technology.

GHIT Fund Announces New Investments: A Total of 2.86 Billion Yen in Drug for Schistosomiasis, Dengue, Malaria and Tuberculosis, Vaccines for Leishmaniasis and Malaria, and Diagnostics for Tuberculosis

Retrieved on: 
Thursday, March 28, 2019
Infectious diseases, Medical specialties, Medicine, RTT, Neglected diseases, Simcyp, Helminthiases, Waterborne diseases, Kenya Medical Research Institute, Praziquantel, Schistosomiasis

Its mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in this age group.

Key Points: 
  • Its mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in this age group.
  • At the end of 2017 Simcyp completed all its tasks around PK modeling and left the Consortium.
  • In Jan 2018 Universit Flix Houphout Boigny (UFHB) and Kenya Medical Research Institute (KEMRI) joined the consortium as new partners.
  • The core project team is supported by various subteams focusing on specific technical and operational aspects to implement the consortium's program.

The Global Virus Network (GVN) Launches Anticipation & Preparedness Taskforce Following 10th International Meeting in Annecy, France

Retrieved on: 
Wednesday, March 27, 2019
Medical specialties, Neglected diseases, Tropical diseases, Microbiology, Biosecurity, Arbovirus, Viral hemorrhagic fever, Virus

In addition, the A&P Taskforce will develop standardized practices and protocols for global biodefense and biosecurity.

Key Points: 
  • In addition, the A&P Taskforce will develop standardized practices and protocols for global biodefense and biosecurity.
  • Of all the challenges that pose a clear and present threat to public health, biosecurity poses one of the greatest global risks.
  • The A&P Taskforce, as well as eight new Virus Watch Groups, were adopted by the Leadership Committee of the GVN at the organization's tenth international meeting in Annecy, France in the Fall of last year.
  • The Virus Watch Groups will enable rapid responses to threats in the following categories: Arboviruses; Gastrointestinal; Hemorrhagic Fever; Herpes; Oncogenic; Respiratory; Retroviruses; and Zoonotic.

African Trypanosomiasis Pipeline Review, H1 2019 - Therapeutic Assessment of 4 Companies & 15 Drug Profiles - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2019
Health, Pharmaceutical, Infectious diseases, Medical specialties, Medicine, Tropical diseases, Neglected diseases, African trypanosomiasis, RTT, Zoonoses

African Trypanosomiasis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for African Trypanosomiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Key Points: 
  • African Trypanosomiasis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for African Trypanosomiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The African Trypanosomiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for African Trypanosomiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide reviews key companies involved in African Trypanosomiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.

Global Dengue Fever Partnering Deals and Agreements Directory 2014-2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2019
Health, Infectious diseases, Pharmaceutical, Dengue fever, Tropical diseases, Neglected diseases, Health

The "Global Dengue Fever Partnering 2014 to 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Dengue Fever Partnering 2014 to 2019" report has been added to ResearchAndMarkets.com's offering.
  • The Global Dengue Fever Partnering Terms and Agreements since 2014 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.
  • Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2014.
  • Global Dengue Fever Partnering Terms and Agreements since 2014 report provides the reader with the following key benefits:
    Insight into key deal terms included in contracts, where disclosed
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190306005522/en/

Take Action for World Rare Disease Day on February 28, 2019

Retrieved on: 
Wednesday, February 27, 2019
Epidemiology, Articles, Medicine, Health, Global Genes, Rare Disease Day, Rare disease, Neglected diseases, Disease

ALISO VIEJO, Calif., Feb. 27, 2019 /PRNewswire/ --In honor of World Rare Disease Day tomorrow, Global Genes , a leading rare disease patient advocacy organization, takes action across the United States as representatives divide and conquer to drive forward momentum for rare disease patients and advocates.

Key Points: 
  • ALISO VIEJO, Calif., Feb. 27, 2019 /PRNewswire/ --In honor of World Rare Disease Day tomorrow, Global Genes , a leading rare disease patient advocacy organization, takes action across the United States as representatives divide and conquer to drive forward momentum for rare disease patients and advocates.
  • Global Genes Founder Nicole Boice is representing the rare disease community at the Rare Disease Day Conference 2019 on March 2nd at Notre Dame's Boler-Parseghian Center for Rare and Neglected Diseases.
  • World Rare Disease Day is an annual observance on the last day of February to raise awareness for the more than 350 million people worldwide affected by rare disease - which is greater than the US population.
  • To take action this Rare Disease Day or to learn more about Global Genes, please visit globalgenes.org .